Edition:
United States

Illumina Inc (ILMN.OQ)

ILMN.OQ on NASDAQ Stock Exchange Global Select Market

301.08USD
20 Nov 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$301.08
Open
$298.19
Day's High
$308.75
Day's Low
$292.62
Volume
549,190
Avg. Vol
368,122
52-wk High
$372.46
52-wk Low
$207.94

Latest Key Developments (Source: Significant Developments)

Illumina Reports Financial Results For Q3 2018
Tuesday, 23 Oct 2018 04:05pm EDT 

Oct 23 (Reuters) - Illumina Inc ::ILLUMINA REPORTS FINANCIAL RESULTS FOR THIRD QUARTER OF FISCAL YEAR 2018.SEES FY 2018 NON-GAAP EARNINGS PER SHARE $5.70 TO $5.75.SEES FY 2018 GAAP EARNINGS PER SHARE $5.32 TO $5.37.Q3 NON-GAAP EARNINGS PER SHARE $1.52.Q3 GAAP EARNINGS PER SHARE $1.33.Q3 REVENUE $853 MILLION VERSUS I/B/E/S VIEW $828.6 MILLION.SEES FY 2018 REVENUE UP ABOUT 20 PERCENT.Q3 EARNINGS PER SHARE VIEW $1.26 -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $5.45, REVENUE VIEW $3.31 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Inscripta Announces Acquisition Of Solana Biosciences
Wednesday, 5 Sep 2018 09:00am EDT 

Sept 5 (Reuters) - Illumina Inc ::INSCRIPTA ANNOUNCES STRATEGIC ACQUISITION OF SOLANA BIOSCIENCES.  Full Article

Illumina Receives Approval Of Miseq DX System In China
Monday, 27 Aug 2018 04:05pm EDT 

Aug 27 (Reuters) - Illumina Inc ::ILLUMINA RECEIVES APPROVAL OF MISEQ DX SYSTEM IN CHINA.ILLUMINA - MISEQDX SEQUENCING SYSTEM RECEIVED APPROVAL CERTIFICATE FROM CHINA NATIONAL DRUG ADMINISTRATION.  Full Article

Illumina Reports Q2 Non-GAAP Earnings Per Share Of $1.43
Monday, 30 Jul 2018 04:05pm EDT 

July 30 (Reuters) - Illumina Inc ::ILLUMINA REPORTS FINANCIAL RESULTS FOR SECOND QUARTER OF FISCAL YEAR 2018.Q2 NON-GAAP EARNINGS PER SHARE $1.43.Q2 GAAP EARNINGS PER SHARE $1.41.Q2 REVENUE $830 MILLION VERSUS I/B/E/S VIEW $786.6 MILLION.SEES FY 2018 NON-GAAP EARNINGS PER SHARE $5.35 TO $5.45.SEES FY 2018 REVENUE UP ABOUT 20 PERCENT.Q2 EARNINGS PER SHARE VIEW $1.11 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 GAAP EARNINGS PER SHARE $5.10 TO $5.20.FY2018 EARNINGS PER SHARE VIEW $4.87, REVENUE VIEW $3.19 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Illumina Acquires Edico Genome To Accelerate Genomic Data Analysis
Tuesday, 15 May 2018 09:00am EDT 

May 15 (Reuters) - Illumina Inc ::ILLUMINA ACQUIRES EDICO GENOME TO ACCELERATE GENOMIC DATA ANALYSIS.  Full Article

Bristol-Myers Squibb And Illumina Announce Collaboration To Develop Companion Diagnostics For Bristol-Myers Squibb's Oncology Immunotherapies
Friday, 13 Apr 2018 04:15pm EDT 

April 13 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB AND ILLUMINA ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE COMPANION DIAGNOSTICS FOR BRISTOL-MYERS SQUIBB’S ONCOLOGY IMMUNOTHERAPIES.EXPANDS ILLUMINA'S ONCOLOGY OFFERINGS FOR NEXTSEQ 550DX.COS PLAN TO DEVELOP A DIAGNOSTIC VERSION OF ILLUMINA TRUSIGHT ONCOLOGY 500 ASSAY TO MEASURE POTENTIALLY PREDICTIVE GENOMIC BIOMARKERS.  Full Article

Loxo Oncology And Illumina To Partner On Developing Pan Cancer Companion Diagnostics
Tuesday, 10 Apr 2018 06:45am EDT 

April 10 (Reuters) - Loxo Oncology::LOXO ONCOLOGY AND ILLUMINA TO PARTNER ON DEVELOPING NEXT-GENERATION SEQUENCING-BASED PAN-CANCER COMPANION DIAGNOSTICS.LOXO ONCOLOGY-PARTNERSHIP TO SEEK APPROVAL FOR VERSION OF ILLUMINA TRUSIGHT TUMOR 170 AS COMPANION DIAGNOSTIC FOR LAROTRECTINIB, LOXO-292 ACROSS TUMORS .LOXO ONCOLOGY - COMPANIES ALSO PLANNING TO BROADEN CLINICAL UTILITY OF FULL PANEL BY OBTAINING REGULATORY APPROVAL FOR OTHER ASSAY CONTENT.  Full Article

Illumina Sees Non-GAAP Diluted EPS Attributable To Illumina Stockholders In Range Of $4.50-$4.60 For Fiscal Year 2018
Thursday, 11 Jan 2018 06:25am EST 

Jan 11 (Reuters) - Illumina Inc ::ILLUMINA INC - SEES NON-GAAP DILUTED EPS ATTRIBUTABLE TO ILLUMINA STOCKHOLDERS IN RANGE OF $4.50 - $4.60 FOR FISCAL YEAR 2018.ILLUMINA - SEES SEES GAAP DILUTED EPS ATTRIBUTABLE TO ILLUMINA STOCKHOLDERS IN RANGE OF $4.14 - $4.24 FOR FISCAL YEAR 2018- SEC FILING.  Full Article

HTG Molecular, Illumina Agreed To Third Development Plan Under Parties' Amended & Restated Development & Supply Agreement
Wednesday, 27 Dec 2017 04:35pm EST 

Dec 27 (Reuters) - HTG Molecular Diagnostics Inc ::HTG MOLECULAR DIAGNOSTICS - ON DEC 23, CO, ILLUMINA AGREED TO THIRD DEVELOPMENT PLAN UNDER PARTIES' AMENDED & RESTATED DEVELOPMENT & SUPPLY AGREEMENT.HTG MOLECULAR DIAGNOSTICS SAYS UNDER PLAN, ILLUMINA EXPECTED TO DEVELOP & DELIVER TO CO EXECUTABLE VERSION OF CUSTOM SOFTWARE - SEC FILING.  Full Article

Luna Dna Announces $2 Mln In Seed Funding Round Included Several Individual Investors And Former Executives From Illumina
Monday, 18 Dec 2017 05:15pm EST 

Dec 18 (Reuters) - Illumina Inc ::LUNA DNA ANNOUNCES $2 MILLION IN SEED FUNDING; ROUND INCLUDED SEVERAL INDIVIDUAL INVESTORS AND FORMER EXECUTIVES FROM ILLUMINA.  Full Article

Illumina to buy rival Pacific Biosciences in $1.2 billion deal

Gene sequencing company Illumina Inc said http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20181101:nBw18KCRQa on Thursday it plans to buy smaller rival Pacific Biosciences of California Inc in an all-cash deal valued at $1.2 billion, expanding its capabilities as the market grows.